Liraglutide studies: 1,219 papers with results
Page 7 of 25
- The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes.
Sivalingam S · Scientific reports · 2021
Randomized controlled trial · 5 results
- Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.
Simeone PG · Cardiovascular diabetology · 2025
Randomized controlled trial · 16 results
- A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
Nomoto H · PloS one · 2015
Randomized controlled trial · 11 results
- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V · Cardiovascular diabetology · 2018
Randomized controlled trial · 9 results
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Khoo J · Liver international : official journal of the International Association for the Study of the Liver · 2019
Randomized controlled trial · 7 results
- GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E · Clinical science (London, England : 1979) · 2017
Randomized controlled trial · 8 results
- Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.
Jensen JK · Frontiers in endocrinology · 2021
Randomized controlled trial · 6 results
- Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.
Xiao Y · Metabolic syndrome and related disorders · 2022
Randomized controlled trial · 7 results
- Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
Anholm C · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 7 results
- Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P · Cardiovascular diabetology · 2021
Randomized controlled trial · 5 results
- Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Feng WH · Journal of diabetes investigation · 2019
Randomized controlled trial · 15 results
- Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Salamun V · European journal of endocrinology · 2018
Randomized controlled trial · 3 results
- Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
Xu Z · Expert review of clinical pharmacology · 2023
Randomized controlled trial · 5 results
- Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Kumarathurai P · Diabetes care · 2017
Randomized controlled trial · 8 results
- Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 3 results
- FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
Dogan ADA · BMC research notes · 2024
Randomized controlled trial · 3 results
- Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
Garg M · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 5 results
- Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.
Ellegaard AM · Clinical and translational gastroenterology · 2024
Randomized controlled trial · 3 results
- Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
Lin L · The Journal of dermatological treatment · 2022
Randomized controlled trial · 8 results
- Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.
Lin K · Computational intelligence and neuroscience · 2022
Randomized controlled trial · 24 results
- Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.
Oosterom-Eijmael MJP · Journal of cardiothoracic and vascular anesthesia · 2024
Randomized controlled trial · 1 result
- Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S · International journal of clinical pharmacology and therapeutics · 2008
Randomized controlled trial · 12 results
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P · Journal of hypertension · 2017
Randomized controlled trial · 7 results
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 12 results
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.
Dietsche KB · The Journal of clinical endocrinology and metabolism · 2024
Randomized controlled trial · 5 results
- Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Jacobsen LV · Journal of clinical pharmacology · 2011
Randomized controlled trial · 6 results
- Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
Aung MM · Diabetologia · 2019
Randomized controlled trial · 10 results
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.
Farr OM · Metabolism: clinical and experimental · 2016
Randomized controlled trial · 5 results
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
Ten Kulve JS · Diabetes care · 2016
Randomized controlled trial · 5 results
- Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Farr OM · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 5 results
- Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R · Cardiovascular diabetology · 2015
Randomized controlled trial · 6 results
- Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
Peradze N · Cardiovascular diabetology · 2019
Randomized controlled trial · 10 results
- Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.
Voukali M · Journal of diabetes research · 2014
Randomized controlled trial · 5 results
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Stefanakis K · Metabolism: clinical and experimental · 2026
Randomized controlled trial · 19 results
- Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U · Diabetes care · 2011
Randomized controlled trial · 8 results
- Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Klein DJ · Diabetes technology & therapeutics · 2014
Randomized controlled trial · 9 results
- Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Breitschaft A · Diabetes research and clinical practice · 2014
Randomized controlled trial · 6 results
- The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A · Advances in therapy · 2011
Randomized controlled trial · 7 results
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 7 results
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
Kapitza C · Advances in therapy · 2011
Randomized controlled trial · 4 results
- Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.
Guerdjikova AI · International journal of psychiatry in clinical practice · 2025
Randomized controlled trial · 14 results
- Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH · Diabetes care · 2014
Randomized controlled trial · 5 results
- A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).
Loganathan J · Journal of diabetes and its complications · 2022
Randomized controlled trial · 4 results
- Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH · Danish medical journal · 2015
Randomized controlled trial · 10 results
- Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Dubé MC · Diabetes, obesity & metabolism · 2018
Randomized controlled trial · 12 results
- Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.
Ilkowitz JT · Journal of diabetes science and technology · 2016
Randomized controlled trial · 9 results
- Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.
Dubé MC · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 9 results
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ · Journal of hepatology · 2016
Randomized controlled trial · 12 results
- Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
Zenz S · The Journal of clinical endocrinology and metabolism · 2022
Randomized controlled trial · 9 results
- One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB · Diabetes · 2004
Randomized controlled trial · 14 results